Abstract
We developed a KEAP1/NFE2L2 pathway signature that robustly predicts functional mutations of KEAP1- and NFE2L2-mutated NSCLC. To determine the prognostic value of this signature, we identified a cohort with KEAP1/NFE2L2 mutations and compared it with a control cohort lacking established targetable driver mutations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
